The Kitchen is empty.
John Lewis of Hungerford (JLH.L, market capitalisation of £2.6m), a kitchen and furniture stores operator nationwide, intends to seek shareholder approval for the cancellation of the Company's ordinary shares from trading on AIM. The Directors consider that the limited free float and liquidity of its ordinary shares, together with costs associated trading on AIM are not commensurate with the associated benefits to the Company.
Character Group 348p £67.2m (CCT.L)
The designers, developers and international distributor of toys, games and giftware, announced its interim results for the six months ended 28 February 2023. Revenue was £57.9m, down 36.3% year-on-year (HY 2022 £90.9m). Profit before tax and highlighted items were £0.5m (HY 2022: £6.5m). Cash and cash equivalents were £10.7m (FY 2022: £20.0m) and the Group has an unutilised headroom of over £50.0m under its banking and other finance facilities. The Board predicted trading performance at the start of this year would be very much one of two halves. The success of Heroes of Goo Jit Zu continues and is supported by other lines, including the influencer inspired Lanky Box and Aphmau products. Hence, the Board is confident of the prospects for the second half and continues to expect that Character's profitability for FY2023 will be in line with current market expectation.
Crossword Cybersecurity* 8.5p £8.0m (CCS.L)
The cybersecurity solutions company focused on cyber strategy and risk, announces its inclusion in the CYBERTECH100, an annual list of 100 of the world's most innovative CyberTech companies. Companies were selected for inclusion in the 4th CyberTech100 based on innovative use of technology to solve a significant industry problem or generate cost savings or efficiency improvements across the security value chain. CYBERTECH100 considers that these are the companies every financial institution needs to know about as they consider and develop their information security and financial crime fighting strategies. Companies that won places on the list generate huge awareness among financial services organisations and the wider cybersecurity community. Many are approached directly by financial institutions while others got a warmer reception from prospective clients and partners.
Ilika 50p 79.2m (IKA.L)
The company focusing on solid-state battery technology, announces it has made a number of first customer shipments of stacked Stereax® M300 batteries from its UK manufacturing facility. Further to its announcement of 11 April 2023, these shipments are the first of a series to customers including CubeWorks, the developer of millimeter-scale smart sensing solutions for IoT, and Lura Health, a leading developer of wearable intraoral biosensors for salivary diagnostics. The small form factor of M300 batteries is of particular interest to Ilika's customers due to their compact, high-density and high-power characteristics.
ImmuPharma 2.605p £8.7m (IMM.L)
The specialist drug discovery and development company, announces its final results for the twelve months ended 31 December 2022. Loss for the period was £3.8m (2021: £8.2m). Research and development expenses totalled £2.0m (2021: £3.7m). Cash balance at year end was £0.7m (2021: £1.6m). During the period, the company raised a total of £2.0m. The company remains on bringing two key late stage clinical assets, Lupuzor™ for lupus and CIDP closer to the market. The clinical roadmap for Lupuzor™ is on track to commence the Phase 2/3 adaptive trial in H2 2023, with potentially CIDP moving into clinical studies in parallel.
Ingenta 112p £16.3m (ING.L)
The provider of software and services to the global publishing industry, announces its final audited results for the year ended 31 December 2022. Revenue increased 4% to £10.5m (2021: £10.1m). Annual Recurring Revenue (ARR) was £9.0m representing 86% of total revenue (2021: £8.9m, 88%). Adjusted EBITDA increased 33% to £2.0m (2021: £1.5m). Cash balances at year end of £2.4m (2021: £3.0m). The Company is seeing strong trading in early 2023, with growth in revenues and profit over the prior period.
Instem 640p £145.71m (INS.L)
The leading provider of IT solutions to the global life sciences market, announces a renewal of its long-standing agreement with the National Toxicology Program (NTP), run by the US National Institute of Environmental Health Sciences (NIEHS). The contract is expected to underpin increased revenue visibility through additional SaaS revenues while also providing significant scope for expansion. The maximum allowable NTP expenditure during this 5-year agreement period is $16.5m. The year one value of this order will be c.$2.0m, including initial recurring revenue of c.$0.9m.
MaxCyte 320p £329.8m (MXCT.L)
The cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialisation of next-generation cell therapeutics and to support innovative, cell-based research, announced financial results for the first quarter ended March 31, 2023. Revenue was $8.6m in Q1 2023, a decrease of 26% year-on-year. Net loss was $10.9m in Q1 2023 compared to net loss of $4.1m for Q1 2022. The Company now expects total revenue for 2023 to grow between 8% and 12% compared to 2022, with core revenue growth of 5% to 10% and Strategic Platform License (SPL) program-related revenue expectations remaining the same at approximately $6m for the year. Cash, cash equivalents and short-term investments were $224.7m as of March 31 2023.
Molecular Energies 127.5p £13.2m (MEN.L)
The international energy company with both hydrocarbon and alternative energy divisions provides an update on its drilling of the exploration well in the Pirity Concession, Chaco, Paraguay. As part of the due diligence testing of the drilling rig, Molecular has insisted that the drilling contractor make certain modifications and repairs to the blow-out preventor, at the contractor's own cost. Due to the complex nature of the blow-out preventor and the requirements for it to be fit for the purpose in this particular exploratory well, it is now anticipated that spudding of the well will take place at or around the end of the first week in July. It is anticipated that the well will take 40 days from the date of spud to reach its target depth. The well will target the Delray complex of prospects, estimated by the Company to contain in aggregate over 260 mmbbls of P50 unrisked resources.
Savannah Energy 26.25p £342.6m (SAVE.L)
The British independent energy company active in Cameroon, Niger and Nigeria announces the signing of a Memorandum of Agreement by Savannah Energy Niger Solar Limited, a wholly owned subsidiary, with the Government of the Republic of Niger for the development of two solar photovoltaic power plants with a combined installed capacity of up to 200 megawatts (MW). The development and construction phases are planned towards the 2025 to 2026 window.
Serinus Energy 410p £112.8m (SENX.L)
The oil company with operations in Romania and Tunisia announce its interim results for the three months ended 31 March 2023. Revenue was $4.9m, down 66% year-on-year (31 March 2022 - $13.4m). Net loss was $1.3m (31 March 2022 – net income $1.0m). Cash balance as at 31 March 2023 was $2.7m (31 December 2022 - $4.9m). The Company realised a net price of $78.87/boe for the three months ended 31 March 2023, down 57% (31 March 2022 - $184.57/boe). Production for the period averaged 691 boe/d, comprising of 163 boe/d in Romania and 528 boe/d in Tunisia.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
